Juvenile Idiopathic Arthritis (JIA) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033


 Juvenile idiopathic arthritis (JIA), also known as juvenile rheumatoid arthritis, refers to a group of conditions involving joint inflammation (arthritis) that first appear before age 16. The term "idiopathic" indicates that the specific cause of the disorder is unknown. Researchers have identified changes in several genes that may influence the risk of developing juvenile idiopathic arthritis. Some of these genes belong to a family of genes that provide instructions for making a group of related proteins called the human leukocyte antigen (HLA) complex.

·       The incidence of Juvenile idiopathic arthritis (JIA) in North America and Europe is estimated to be 4 to 16 in 10,000 children

 

Thelansis’s “Juvenile Idiopathic Arthritis (JIA) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Juvenile Idiopathic Arthritis (JIA) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Juvenile Idiopathic Arthritis (JIA) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Juvenile Idiopathic Arthritis (JIA) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Juvenile Idiopathic Arthritis (JIA) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Juvenile Idiopathic Arthritis (JIA), Juvenile Idiopathic Arthritis (JIA) market outlook, Juvenile Idiopathic Arthritis (JIA) competitive landscape, Juvenile Idiopathic Arthritis (JIA) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)

Comments

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Metabolic Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Type 1 Diabetes Mellitus (T1D) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033